About this event
This webinar is the first in a two-part series designed to support primary care teams with the forthcoming changes to GLP-1 prescribing for obesity. It will focus on the wider context, contractual requirements, and obesity management pathways. A second webinar, taking place the following week, will provide detailed practical guidance on initiating and monitoring GLP-1 therapy, including patient counselling, prescribing considerations, and administration techniques. We encourage attendees to register for both sessions to gain a comprehensive understanding of the changes and their implementation in practice.
The National Picture
- Initial approach to Mounjaro – and national (NHSE) change in direction of travel
- NHSE eligibility criteria and SEL eligible NHSE Mounjaro cohort numbers
- 26/27 GP Contract - new QOF obesity indicators
Assessment and Decision-Making
- Overview of clinical considerations
- Assessment of patient and tirzepatide initiation considerations
- Wider possible treatment options – linking the new QOF indicator OB004 (not just medicines, including when bariatric surgery referral may be helpful)
Q&A
Hosted by
-
External speaker
Robert McCarthyRM E
-
External speaker
Piya Sen GuptaPS E
-
Team member
Juliet GrenhamJG T
-
External speaker
Anna HodgkinsonAH E
-
External speaker
Anna HodgkinsonAH E
-
External speaker
Krishna SubbarayanKS E
-
External speaker
Abhiti GulatiAG E
South East London Workforce Development Hub
Developing the Primary Care Workforce in South East LondonEducation, Professional Development and Workforce provider across Primary Care in South East London
